Wegovy five-month results: what the evidence says and what it means for you

What the clinical data actually shows at the five-month stage

The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and is the most-cited evidence base for semaglutide 2.4mg's weight-loss effect. It did not report a standalone five-month figure, but the trial's trajectory is well understood: weight loss accelerates through the dose-escalation phase and peaks in rate around weeks 16–24, which maps almost exactly onto months four through six for people who started on the standard 0.25mg ramp. If you want to understand what sits just behind this window, our page on Wegovy 4 month results covers what the evidence shows at that earlier stage. By week 20, participants were typically seeing losses of 10–13% of their starting body weight.

That range matters. Some people will be above it; some below. Genetics, metabolic rate, how consistently the injection routine has been followed, and whether a dose increase has been tolerated on schedule all pull the number in different directions. The NHS medicines page for semaglutide notes that common side effects, particularly nausea, can disrupt eating patterns in ways that temporarily skew the scale, not always in a useful direction.

Five months is also often the point at which a prescriber will review whether you have reached 2.4mg, or whether an adverse reaction has slowed titration. That clinical context shapes the result more than most people realise. A result that looks modest may reflect a slower dose schedule for good clinical reasons, not a lack of response to the medicine.

The factors that pull five-month results apart

Two people starting Wegovy on the same day with the same BMI can look very different at month five. That is not a flaw in the data; it is what the trial results already told us. The STEP 1 figures are averages across nearly two thousand participants, and the distribution around that average is wide.

Adherence to the weekly injection schedule is one of the biggest variables. Missing doses, rotating them by several days, or skipping an escalation step on clinical advice all affect where someone lands at the five-month mark. Diet matters too, though not in a simple calorie-counting way, the appetite suppression that semaglutide produces tends to reduce overall intake, but protein adequacy and hydration on lower food volumes become more significant, not less.

Physical activity is a secondary factor in the short term but compounds over time. Strength training in particular helps preserve lean mass during weight loss, which affects both the scale number and how sustainable the result feels. If you are curious about the general trajectory, how long Wegovy takes to work covers the early-phase mechanics in more detail.

Finally, the dose at month five matters enormously. Someone who reached 2.4mg at week 16 and has spent two months on it will typically have a stronger result than someone still escalating. The maintenance dose is where the medicine's effect stabilises rather than grows.

When five-month results should prompt a clinical conversation

NICE guidance on semaglutide (Wegovy), published as TA875, includes a review point: if less than 5% body weight has been lost after six months on the maintenance dose, continuing the treatment is reconsidered. Five months is not yet that threshold, but it is a sensible time to look at the trend honestly.

If you have been on 2.4mg for two months and the scale has barely moved, that is worth discussing with a prescriber before month six. If you are still on 1.7mg because 2.4mg caused persistent nausea, your five-month number reflects that titration history, and continuing rather than stopping is usually the right clinical call. These are not decisions anyone should make without input from a clinician who knows their full picture.

Side effects at this stage are usually quieter than in the first eight weeks. Most people find that nausea, the most common complaint, settles within a couple of weeks of each new dose. Persistent symptoms, or anything severe (especially intense stomach pain that radiates toward the back) always need prompt medical attention rather than waiting for the next check-in. Report anything concerning to a doctor or use the MHRA Yellow Card service to flag it formally.

What months six through twelve tend to add, and why the decision to continue is worth making carefully

The weight loss recorded at five months is real, but it is rarely the full picture. In the STEP 1 trial, participants continued to lose weight through to around week 60–68 before plateauing. Month five sits in the middle of the most productive period of treatment for most people, not at the end of it.

The six-month results page covers what the evidence shows at that formal review milestone. But the general principle is that stopping early (unless there is a clinical reason to) tends to leave progress on the table. Weight regain after stopping GLP-1 medicines is well documented, and it tends to happen fairly quickly without the appetite-regulatory effect in place. For those who want to build a fuller picture of how results develop over time, our page on Wegovy 1 month results shows what the very earliest stage of treatment typically looks like.

For those still deciding whether to start, or comparing options, the Wegovy overview covers the full licensed indication and access routes. The weight-loss treatments overview is useful if you are weighing Wegovy against other licensed options. Cost context (because private treatment pricing is a real consideration) is covered on the Wegovy access and pricing page.

If you are ready to talk through where you are at, or want to start treatment with clinical oversight from the outset, you can speak to our prescribers through a free consultation. Start your free consultation here.